We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
(+2.7%)
Cap. Flow
-$19.3M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$25.6M |
| 2 |
Tompkins Financial
TMP
|
+$13.1M |
| 3 |
AGEN
Agenus
AGEN
|
+$6.13M |
| 4 |
MannKind Corp
MNKD
|
+$5.33M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$3.71M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$28.4M |
| 2 |
AbbVie
ABBV
|
+$14.7M |
| 3 |
Zoetis
ZTS
|
+$14.2M |
| 4 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$11.5M |
| 5 |
Arrowhead Research
ARWR
|
+$8.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 89.38% |
| 2 | Healthcare | 10.49% |
| 3 | Financials | 0.07% |
| 4 | Technology | 0.07% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
Vertex Pharmaceuticals
VRTX
$132B
| $189M | 12.26% |
24,890
+1,825
| +8% | +$145K |
|
2
CALL
Merck
MRK
$357B
| $82.2M | 5.34% |
18,086
+4,205
| +30% | +$192K |
|
3
CALL
Acadia Pharmaceuticals
ACAD
$4.74B
| $82M | 5.33% |
29,842
+4,660
| +19% | +$97.4K |
|
4
PUT
Sarepta Therapeutics
SRPT
$2.21B
| $61.5M | 4% |
13,028
+7,557
| +138% | +$291K |
|
5
PUT
iShares S&P 100 ETF
OEF
$20.2B
| $61M | 3.97% |
5,728
+3,728
| +186% | +$280K |
|
6
PUT
iShares MSCI Australia ETF
EWA
$1.29B
| $59.5M | 3.87% |
+50,000
| New | +$1.2M |
|
7
PUT
Gilead Sciences
GILD
$182B
| $53.5M | 3.47% |
8,506
+976
| +13% | +$58.3K |
|
|
8
PUT
Vertex Pharmaceuticals
VRTX
$132B
| $49.7M | 3.23% |
6,551
+1,294
| +25% | +$103K |
|
|
9
CALL
iShares S&P 100 ETF
OEF
$20.2B
| $45.2M | 2.94% |
+4,250
| New | +$320K |
|
10
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
| $37.8M | 2.46% |
2,250
-2,250
| -50% | -$377K |
|
11
CALL
GSK
GSK
$100B
| $32.8M | 2.13% |
+5,225
| New | +$336K |
|
12
CALL
Regeneron Pharmaceuticals
REGN
$81.7B
| $31.3M | 2.04% |
1,001
-1,136
| -53% | -$299K |
|
|
MDVN
13
PUT
DELISTED
MEDIVATION, INC.
MDVN
| $29.5M | 1.92% |
9,836
+7,308
| +289% | +$209K |
|
14
CALL
Bristol-Myers Squibb
BMY
$131B
| $28.4M | 1.85% |
6,139
+4,444
| +262% | +$195K |
|
|
AEGR
15
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
| $26.4M | 1.72% |
3,079
+709
| +30% | +$60.1K |
|
|
16
Vertex Pharmaceuticals
VRTX
$132B
| $25.5M | 1.66% |
336,955
+321,847
| +2,130% | +$25.6M |
|
|
17
Sarepta Therapeutics
SRPT
$2.21B
| $24.7M | 1.6% |
522,041
+67,142
| +15% | +$2.59M |
|
|
AGN
18
CALL
DELISTED
Allergan Inc
AGN
| $23M | 1.49% |
2,540
-1,059
| -29% | -$95.1K |
|
|
AEGR
19
DELISTED
Aegerion Pharmaceuticals
AEGR
| $22.2M | 1.44% |
259,119
-334,743
| -56% | -$28.4M |
|
20
CALL
Biogen
BIIB
$32.1B
| $21M | 1.37% |
+874
| New | +$196K |
|
|
21
CALL
MannKind Corp
MNKD
$1.21B
| $20M | 1.3% |
7,026
-734
| -9% | -$24.3K |
|
|
AEGR
22
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
| $18.9M | 1.23% |
2,200
+1,065
| +94% | +$90.3K |
|
|
AGN
23
PUT
DELISTED
Allergan Inc
AGN
| $18.4M | 1.2% |
2,033
+1,528
| +303% | +$137K |
|
|
CELG
24
PUT
DELISTED
Celgene Corp
CELG
| $18.1M | 1.18% |
2,356
+1,208
| +105% | +$84.7K |
|
25
CALL
Opko Health
OPK
$1.16B
| $16.8M | 1.09% |
+19,032
| New | +$153K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q3 2013 Portfolio in Review
As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.
- Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
- Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
- Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
- Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
- Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
- Sabby Management opened 90 new positions and closed 65 in Q3 2013.
- Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.
Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.